Newlink Genetics Corp (NLNK): Charles J. Jr. Link , Chairman of the Board and CEO of Newlink Genetics Corp sold 10,000 shares on Apr 7, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $20.02 per share for a total value of $200,250.00.
Company has been under the radar of several Street Analysts.NewLink Genetics Corp is Initiated by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $27. The Rating was issued on Mar 23, 2016.NewLink Genetics Corp is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 52 from a previous price target of $62 . The Rating was issued on Mar 1, 2016.
Currently the company Insiders own 12.3% of NewLink Genetics Corp shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -17.82%.Institutional Investors own 56.12% of NewLink Genetics Corp shares.During last six month period, the net percent change held by insiders has seen a change of -28.79%.
Shares of NewLink Genetics Corp (NLNK) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.5 points or -2.67% at $18.26 with 3,45,135 shares getting traded. Post opening the session at $18.79, the shares hit an intraday low of $18.2 and an intraday high of $19.35 and the price vacillated in this range throughout the day. The company has a market cap of $527 M and the number of outstanding shares has been calculated to be 2,88,58,536 shares. The 52-week high of NewLink Genetics Corp is $58.45 and the 52-week low is $15.68.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system’s tolerance to cancer by inhibiting the indoleamine-(2 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.